



ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences

May 8, 2006

SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences:

- The Rodman & Renshaw 3rd Annual Global Healthcare Conference on Monday, May 15, 2006, at 10:50 a.m. Central European Time at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
- The Banc of America Health Care Conference on Wednesday, May 17, 2006, at 1:20 p.m. Pacific Time at The Four Seasons Hotel in Las Vegas, Nevada.
- The BioEquity Europe 2006 Conference on Monday, May 22, 2006, at 11:00 a.m. Central European Time at The Frankfurt Marriott Hotel in Frankfurt, Germany.

Live webcasts of ACADIA's presentations at each of the Rodman & Renshaw and Banc of America Conferences will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through May 31, 2006.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five Phase II-stage clinical programs as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson's disease, sleep maintenance insomnia, and neuropathic pain. All of the drug candidates in ACADIA's product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmö, Sweden.

Contacts:

ACADIA Pharmaceuticals Inc.

Lisa Barthelemy, Director, Investor Relations

Thomas H. Aasen, Vice President and Chief Financial Officer

(858) 558-2871